Results of large trials in adult acute lymphoblastic leukemia (ALL).*
| Study . | Year . | N . | Median Age (Range) . | SCT . | CR Rate . | Early Death . | Survival . |
|---|---|---|---|---|---|---|---|
| Abbreviations: Ph+, SCT in Philadelphia chromosome–positive ALL; PO, prospective SCT in all pts with donor; PR, SCT according to prospective risk model; HR, prospective SCT in a study for HR patients only; n.r. not reported. | |||||||
| * Survival of CR patients | |||||||
| CALGB 9111, USA5 | 1998 | 198 | 35 (16–83) | Ph+ | 85% | 8% | 40% (3 y) |
| LALA 87, France1 | 2000 | 572 | 33 (15–60) | PO | 76% | 9% | 27% (10 y) |
| NILG 08/96, Italy7 | 2001 | 121 | 35 (15–74) | PR | 84% | 8% | 48% (5 y) |
| GMALL 05/93, Germany8 | 2001 | 1163 | 35 (15–65) | PR | 83% | n.r. | 35% (5 y) |
| JALSG-ALL93, Japan2 | 2002 | 263 | 31 (15–59) | PO | 78% | 6% | 30% (6 y) |
| UCLA, USA9 | 2002 | 84 | 27 (16–59) | PR | 93% | 1% | 47% (5 y) |
| Sweden10 | 2002 | 153 | 42 (16–82) | PR | 75% | n.r. | 28% (5 y) |
| GIMEMA 0288, Italy12 | 2002 | 767 | 28 (12–60) | — | 82% | 11% | 27% (9 y) |
| MD Anderson, USA6 | 2004 | 288 | 40 (15–92) | Ph+ | 92% | 5% | 38% (5 y) |
| EORTC ALL-3, Europe3 | 2004 | 340 | 33 (14–79) | PO | 74% | n.r. | 36%*(6 y) |
| LALA 94, France11 | 2004 | 922 | 33 (15–55) | PR | 84% | 5% | 36% (5 y) |
| GOELAL02, France13 | 2004 | 198 | 33 (15–59) | HR | 86% | 2% | 41% (6 y) |
| MRC XII/ECOG E 2993, UK-USA4 | 2005 | 1521 | 15–59 | PO | 91% | n.r. | 38% (5 y) |
| GIMEMA 0496, Italy14 | 2005 | 450 | 16–60 | n.r. | 80% | n.r. | 33% (5 y) |
| Pethema ALL-93, Spain15 | 2005 | 222 | 27 (15–50) | HR | 82% | 6% | 34% (5 y) |
| Weighted mean | 7262 | 84% | 7% | 35% | |||
| Study . | Year . | N . | Median Age (Range) . | SCT . | CR Rate . | Early Death . | Survival . |
|---|---|---|---|---|---|---|---|
| Abbreviations: Ph+, SCT in Philadelphia chromosome–positive ALL; PO, prospective SCT in all pts with donor; PR, SCT according to prospective risk model; HR, prospective SCT in a study for HR patients only; n.r. not reported. | |||||||
| * Survival of CR patients | |||||||
| CALGB 9111, USA5 | 1998 | 198 | 35 (16–83) | Ph+ | 85% | 8% | 40% (3 y) |
| LALA 87, France1 | 2000 | 572 | 33 (15–60) | PO | 76% | 9% | 27% (10 y) |
| NILG 08/96, Italy7 | 2001 | 121 | 35 (15–74) | PR | 84% | 8% | 48% (5 y) |
| GMALL 05/93, Germany8 | 2001 | 1163 | 35 (15–65) | PR | 83% | n.r. | 35% (5 y) |
| JALSG-ALL93, Japan2 | 2002 | 263 | 31 (15–59) | PO | 78% | 6% | 30% (6 y) |
| UCLA, USA9 | 2002 | 84 | 27 (16–59) | PR | 93% | 1% | 47% (5 y) |
| Sweden10 | 2002 | 153 | 42 (16–82) | PR | 75% | n.r. | 28% (5 y) |
| GIMEMA 0288, Italy12 | 2002 | 767 | 28 (12–60) | — | 82% | 11% | 27% (9 y) |
| MD Anderson, USA6 | 2004 | 288 | 40 (15–92) | Ph+ | 92% | 5% | 38% (5 y) |
| EORTC ALL-3, Europe3 | 2004 | 340 | 33 (14–79) | PO | 74% | n.r. | 36%*(6 y) |
| LALA 94, France11 | 2004 | 922 | 33 (15–55) | PR | 84% | 5% | 36% (5 y) |
| GOELAL02, France13 | 2004 | 198 | 33 (15–59) | HR | 86% | 2% | 41% (6 y) |
| MRC XII/ECOG E 2993, UK-USA4 | 2005 | 1521 | 15–59 | PO | 91% | n.r. | 38% (5 y) |
| GIMEMA 0496, Italy14 | 2005 | 450 | 16–60 | n.r. | 80% | n.r. | 33% (5 y) |
| Pethema ALL-93, Spain15 | 2005 | 222 | 27 (15–50) | HR | 82% | 6% | 34% (5 y) |
| Weighted mean | 7262 | 84% | 7% | 35% | |||